Clinical Trial Update: Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly [Phase 1]

View source ↗

Summary

This clinical trial update reports a Phase 1 study comparing daily versus weekly subcutaneous semaglutide dosing; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• OZEMPIC (semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Healthy | Phase 1 | Status: COMPLETED